CJC-1295 and ipamorelin
CJC-1295 and ipamorelin: what each one is, FDA status, the safety concerns FDA has raised and what human data exist.
Not FDA-approved · Evidence grade C · Reviewed
CJC-1295 and ipamorelin (Often sold as a blend). Growth hormone secretagogues.
CNot FDA-approved. Evidence grade C: limited, early or dated human data.
What are CJC-1295 and ipamorelin?
CJC-1295 is an analog of growth-hormone-releasing hormone. Ipamorelin is a growth hormone secretagogue. Both push the pituitary to release growth hormone and they are commonly paired.
Are CJC-1295 and ipamorelin FDA-approved?
Neither is approved, and neither has an FDA drug application on record. FDA flagged both in 2023, and neither was among the six peptides reviewed in July 2026.
What does the evidence show for CJC-1295 and ipamorelin?
Early-phase human studies exist. There are no large controlled trials for the body-composition and anti-aging uses they are sold for.
What are the known risks of CJC-1295 and ipamorelin?
FDA has cited possible immune reactions and peptide-related impurities.
How are CJC-1295 and ipamorelin measured?
A blend vial can be entered using the second-compound field. Products sold online as "research use only" have no assurance of identity, dose or sterility. The calculator can do the arithmetic for any vial, but it cannot tell you what is actually in one.
Sources: Portrait: CJC-1295 and ipamorelin FDA status; FDA: bulk drug substances that may present significant safety risks. This profile does not recommend any dose or use.
For research and educational use. Not medical advice. Regulatory status changes, so confirm the current position with FDA or a licensed professional.